Taysha Gene Therapies (TSHA) Set to Announce Quarterly Earnings on Monday

Taysha Gene Therapies (NASDAQ:TSHA) will issue its quarterly earnings data before the market opens on Monday, August 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same quarter last year, the firm posted ($0.28) EPS. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA traded up $0.12 during trading hours on Tuesday, reaching $2.14. 701,987 shares of the company were exchanged, compared to its average volume of 2,553,927. The stock’s 50-day moving average is $2.75 and its 200-day moving average is $2.53. Taysha Gene Therapies has a twelve month low of $0.69 and a twelve month high of $4.32. The firm has a market cap of $400.22 million, a PE ratio of -4.35 and a beta of 0.41. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75.

Insider Buying and Selling

In other news, major shareholder Paul B. Manning acquired 1,333,333 shares of Taysha Gene Therapies stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now owns 1,333,333 shares in the company, valued at approximately $2,999,999.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TSHA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. BMO Capital Markets started coverage on shares of Taysha Gene Therapies in a report on Thursday, June 27th. They set an “outperform” rating and a $5.00 target price on the stock. Piper Sandler cut their price objective on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a research report on Monday, July 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 target price (up from $2.00) on shares of Taysha Gene Therapies in a research report on Tuesday, May 14th. Finally, JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.60.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.